H.C. Wainwright analyst Brandon Folkes has elevated the price target for PolyPid (PYPD, Financial) from $11 to $13, while maintaining a Buy rating. This decision comes after the release of encouraging results from the SHIELD II Phase 3 trial, evaluating D-PLEX100 for preventing surgical site infections.
The analyst increased the probability of success for D-PLEX100 to 90% in the U.S. and 85% in the EU, up from 80% in both regions. These developments are seen as a substantial positive, reinforcing a strong outlook for PolyPid shares. The promising trial data not only supports the approval and market potential for D-PLEX100 but also underscores the broader applicability of PolyPid’s Plex platform.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $10.75 with a high estimate of $13.00 and a low estimate of $9.00. The average target implies an upside of 188.98% from the current price of $3.72. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
PYPD Key Business Developments
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- PolyPid Ltd (PYPD, Financial) successfully concluded enrollment of the Shield 2 phase 3 trial, which is a significant milestone for the company.
- The company anticipates submitting a new drug application (NDA) for Dplex 100 in early 2026, leveraging fast track and breakthrough therapy designations.
- PolyPid Ltd (PYPD) has secured $15 million in financing, extending its cash runway into the third quarter of 2025.
- There is growing interest from potential US partners for Dplex 100, indicating strong commercial potential.
- The total addressable market for Dplex 100 in the US is substantial, with over 12 million surgeries annually, providing a significant commercial opportunity.
Negative Points
- PolyPid Ltd (PYPD) reported a net loss of $8.3 million for the first quarter of 2025, an increase from the $6.4 million loss in the same period of 2024.
- Research and development expenses increased to $6.1 million, up from $5.1 million in the previous year, driven by the Shield 2 trial.
- The company has not finalized its pricing strategy for Dplex 100, which could impact future revenue projections.
- There are uncertainties regarding the FDA inspection readiness and capacity to meet demand post-launch.
- The company's cash and cash equivalents stand at $8 million, which may not be sufficient if additional funding is not secured.
